Benzinga
06 Apr 2026, 17:41 UTC · 22w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Viridian Therapeutics' elegrobart Phase 3 REVEAL-1 trial yielded proptosis responder rates of 54-63%, falling below investor expectations of 51%-73% for placebo-adjusted rates. — Missed efficacy targets in a pivotal Phase 3 trial directly threaten the commercial viability and market share of the lead drug candidate.
-0.80Amgen's TEPEZZA Phase 3 OBI trial met its primary endpoint with a 77% proptosis response rate, increasing competitive pressure on Viridian. — Strong data from a primary competitor reinforces the benchmark for efficacy, making Viridian's lower rates more problematic.
-0.60The FDA has a PDUFA target action date of June 30 for Viridian's veligrotug application, which is currently under Priority Review. — An upcoming regulatory decision provides a near-term catalyst that could offset current negative sentiment if approval is granted.
+0.40Continue reading
5 related stories
Search tags
Viridian Therapeutics ended fiscal 2025 with $875 million in cash, intended to fund operations through to profitability. — Strong liquidity reduces the immediate risk of dilutive financing despite the stock price drop.
+0.20Which stocks this story touches
[mutual] Both companies are developing and marketing treatments for thyroid eye disease (TED), with Viridian's elegrobart competing against Amgen's TEPEZZA.
[mutual] Both companies targeted the thyroid eye disease (TED) market.
[mutual] Argenx was developing efgartigimod for TED, the same market Viridian is targeting, although Argenx recently discontinued those studies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1d ago
